CIK 0001706431 · Large accelerated filer
Vir Biotechnology, Inc.
Sign in to watch- Ticker
- VIR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812730369
- Phone
- 415-906-4324
- Business address
- 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,939
- in 1 filing, $42K under 10b5-1 plans
Net −$41,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-01-15 | Virgin Herbert EVP, Research & CSO | Sale | −10,530 | $38.00 | $400K | 33,200 |
| 2021-01-15 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −10,530 | 411,455 | ||
| 2021-01-12 | Virgin Herbert EVP, Research & CSO | Option exercise | +3,805 | $1.53 | $6K | 37,005 |
| 2021-01-12 | Virgin Herbert EVP, Research & CSO | Sale | −3,805 | $29.36 | $112K | 33,200 |
| 2021-01-12 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −3,805 | 421,985 | ||
| 2021-01-04 | Parrish Jay Chief Business Officer | Option exercise | +6,945 | $1.49 | $10K | 229,167 |
| 2021-01-04 | Parrish Jay Chief Business Officer | Sale | −6,945 | $26.32 | $183K | 222,222 |
| 2020-12-24 | Virgin Herbert EVP, Research & CSO | Option exercise | +9,500 | $1.53 | $15K | 33,200 |
| 2020-12-24 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −9,500 | 425,790 | ||
| 2020-12-22 | Virgin Herbert EVP, Research & CSO | Option exercise | +3,805 | $1.53 | $6K | 27,505 |
| 2020-12-22 | Virgin Herbert EVP, Research & CSO | Sale | −3,805 | $31.19 | $119K | 23,700 |
| 2020-12-22 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −3,805 | 435,290 | ||
| 2020-12-09 | Hatfield Jeffrey S. Director | Grant or award · Stock Option (Right to Buy) | +46,500 | 46,500 | ||
| 2020-12-08 | Virgin Herbert EVP, Research & CSO | Option exercise | +3,805 | $1.53 | $6K | 27,505 |
| 2020-12-08 | Virgin Herbert EVP, Research & CSO | Sale | −3,805 | $31.27 | $119K | 23,700 |
| 2020-12-08 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −3,805 | 439,095 | ||
| 2020-12-01 | Parrish Jay Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −6,945 | 16,203 | ||
| 2020-12-01 | Parrish Jay Chief Business Officer | Option exercise | +4,630 | $1.49 | $7K | 226,852 |
| 2020-12-01 | Parrish Jay Chief Business Officer | Option exercise | +2,315 | $1.58 | $4K | 229,167 |
| 2020-12-01 | Parrish Jay Chief Business Officer | Sale | −6,945 | $31.53 | $219K | 222,222 |
Page 47 of 54 · 1,063 trades